Showing results (221-230 of 297) with videos related to
Sort By:
Pageof 30
British Journal of Haematology|June 28, 2019
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.Journal of Cutaneous Pathology|September 9, 2017
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemiaSanam Loghavi, Jonathan L Curry, Guillermo Garcia-Manero, et al.Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.Journal of Hematology & Oncology|June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsSankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.Leukemia & Lymphoma|October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapyJorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.Pageof 30